FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Schneider

Research Profile

Procedures

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Mark I Furman; Dean J Kereiakes; Lori A Krueger; Michele N Mueller; Thomas M Broderick; John F Schneider; Wendy L Howard; Marsha L Fox; Marc R Barnard; Andrew L Frelinger; Alan D Michelson
Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
John J Young; Daniel P Marcus; Charles W Abbottsmith; Thomas M Broderick; Joseph K Choo; John Paul Runyon; John F Schneider; Thomas M Shimshak; Rodney P Geier; Dean J Kereiakes
Durable clinical benefit following Sr90 Beta irradiation therapy for in-stent restenosis in high-volume community practice.
Mark I Furman; Dean J Kereiakes; Lori A Krueger; Michele N Mueller; K Pieper; Thomas M Broderick; John F Schneider; Wendy L Howard; Marsha L Fox; Marc R Barnard; Andrew L Frelinger; Alan D Michelson
Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Schneider (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2003: Mark I Furman; Dean J Kereiakes; Lori A Krueger; Michele N Mueller; Thomas M Broderick; John F Schneider; Wendy L Howard; Marsha L Fox; Marc R Barnard; Andrew L Frelinger; Alan D Michelson
Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
American heart journal 2003;145(2):e6.
2003: John J Young; Daniel P Marcus; Charles W Abbottsmith; Thomas M Broderick; Joseph K Choo; John Paul Runyon; John F Schneider; Thomas M Shimshak; Rodney P Geier; Dean J Kereiakes
Durable clinical benefit following Sr90 Beta irradiation therapy for in-stent restenosis in high-volume community practice.
The Journal of invasive cardiology 2003;15 Suppl A():9A-13A.
2001: Mark I Furman; Dean J Kereiakes; Lori A Krueger; Michele N Mueller; K Pieper; Thomas M Broderick; John F Schneider; Wendy L Howard; Marsha L Fox; Marc R Barnard; Andrew L Frelinger; Alan D Michelson
Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
American heart journal 2001;142(5):790-8.
2001: E J Dippel; Dean J Kereiakes; D A Tramuta; Thomas M Broderick; Thomas M Shimshak; EM Roth; CR Hattemer; John Paul Runyon; DD Whang; John F Schneider; Charles W Abbottsmith
Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2001;52(3):279-86.
2000: Dean J Kereiakes; Robert Obenchain; B L Barber; A Smith; M McDonald; Thomas M Broderick; John Paul Runyon; Thomas M Shimshak; John F Schneider; CR Hattemer; EM Roth; DD Whang; D Cocks; Charles W Abbottsmith
Abciximab provides cost-effective survival advantage in high-volume interventional practice.
American heart journal 2000;140(4):603-10.
2000: D A Tramuta; Dean J Kereiakes; E J Dippel; R Lengerich; Thomas M Broderick; Charles W Abbottsmith; DD Whang; EM Roth; John F Schneider; Wendy L Howard; Thomas M Shimshak
Combination enoxaparin-abciximab therapy during coronary intervention: the next standard of care?
The Journal of invasive cardiology 2000;12 Suppl C():3C-6C.